Duchenne muscular dystrophy (DMD) is a disease that is characterized by progressive degeneration of the skeletal, cardiac and smooth muscles, as well as neurons. DMD is caused by mutations in the Dystrophin gene, however the pathogenesis for DMD is not yet clear. Mutations in the C.elegans Dystrophin homolog (
dys-1), lead to hyper-contraction, hyperactivity and an increased Acetylcholine (Ach) level. They also have infrequent body wall muscle degeneration, that can be greatly enhanced in the background of a weak mutation affecting the myogenic factor MyoD (Harte et al, 1998 ; Gieseler et al, 2000 ; comments in Chamberlain and Benian, 2000). We use this
dys-1; CeMyoD double mutant as a model for DMD, as it exhibits progressive muscle degeneration. Studies in numerous model organisms, including C.elegans, indicate that loss of dystrophin or associated proteins lead to defects in Acetylcholine (Ach) transmission at the neuromuscular junction, and this may play a role in the pathophysiology of DMD. Previous genetic studies using our DMD worm model have shown that muscle degeneration is suppressed by mutations that inhibit cholinergic transmission (
unc-13) or calcium influx (egl-19n582) (Mariol et al, 2001; 2007); because these mutations lead to muscle inactivity, it is impossible to conclude whether the suppression of muscle degeneration is due to muscle inactivity and/or to the suppression of another Ach induced effect. We have recently shown a mutation of
pkc-2 reduces muscle degeneration in the DMD worm by almost 50%. There is currently some question as to PKC-2 localisation, and therefore the role of
pkc-2 mutations in DMD pathology. A
pkc-2 transgene, under a lac-Z promoter, has been shown to localise in both muscles and neurons; however, the PKC-2 antibody was observed only in neurons. (Islas-Trejo et al, 1997). GFP::
pkc-2 transgenes, expressed as extrachromosomal arrays or integrated with MOSTIC have been observed in the neurons, neural cell bodies, vulva, and spermatheca, with no signal in muscles. The
pkc-2 mutant was shown to have increased resistance to the Ach esterase inhibitor aldicarb, indicating it may affect Ach neurotransmission. Interestingly,
pkc-2 mutants do not exhibit any obvious muscle activity phenotype. Loss of function mutations in both
pkc-2 and
unc-13 have been shown to suppress the DMD worm phenotype, yet no suppression was seen with RNAi. As neuronal expressed genes are relatively resistant to RNAi (Kamath et al, 2001), we think this is further evidence to suggest that the role of PKC-2 is in fact neural vs. muscular.